{name}
{subtitle}
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
city
~11 mi. (Concord, North Carolina, +240 more cities)
facility
Atrium Health Cabarrus/LCI-Concord
condition
Endometrial Adenocarcinoma, +5 more conditions
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
city
~11 mi. (Concord, North Carolina, +235 more cities)
facility
Atrium Health Cabarrus/LCI-Concord
drug
abiraterone, +9 more drugs
drug type
hormone therapy, +2 more types
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
city
~11 mi. (Concord, North Carolina, +224 more cities)
facility
Atrium Health Cabarrus/LCI-Concord
condition
Hypopharyngeal Carcinoma, +3 more conditions
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +3 more types
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
city
~11 mi. (Concord, North Carolina, +822 more cities)
facility
Atrium Health Cabarrus/LCI-Concord
biomarker
ER Negative, +2 more biomarkers
drug
carboplatin, +3 more drugs